The landscape of obesity medicine has undergone a seismic shift over the last three years. With the meteoric rise of GLP-1 receptor agonists like semaglutide (Wegovy) and dual-agonists like tirzepatide…
The landscape of obesity medicine is undergoing a seismic shift. In recent years, the arrival of GLP-1 receptor agonists—such as semaglutide (Wegovy) and tirzepatide (Zepbound)—has revolutionized how clinicians approach chronic…
The landscape of obesity medicine is currently undergoing a radical transformation. For millions of people, the introduction of GLP-1 receptor agonists—such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro)—has provided…
The landscape of obesity medicine is undergoing a seismic shift. In just a few short years, we have moved from a lack of effective pharmacological interventions to a "golden age"…
Ali Ikhwan
Basiran
Lina Irawan
Nana Wu